var data={"title":"Levothyroxine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Levothyroxine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6457?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=levothyroxine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Levothyroxine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=levothyroxine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Levothyroxine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709010\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Weight reduction:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid hormones, including levothyroxine, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines, such as those used for their anorectic effects.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188360\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Levoxyl;</li>\n      <li>Synthroid;</li>\n      <li>Tirosint;</li>\n      <li>Unithroid;</li>\n      <li>Unithroid Direct</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188361\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Eltroxin;</li>\n      <li>Synthroid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188382\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Thyroid Product</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188365\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Doses should be adjusted based on clinical response and laboratory parameters.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypothyroidism:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Adults (healthy) who have been hypothyroid for only a few months</i>: Initial: 1.6 mcg/kg/day; adjust dose by 12.5 to 25 mcg/day every 4 to 6 weeks as needed. Usual doses are &le;200 mcg/day (range: 100 to 125 mcg/day [70 kg adult]); doses &ge;300 mcg/day are rare (consider poor compliance, malabsorption, and/or drug interactions).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Adults &gt;50 years of age without evidence of coronary heart disease (off-label): </i>Lower starting doses (eg, 50 mcg/day) may be preferred (ATA/AACE [Garber 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Adults with cardiac disease:</i> Initial: 12.5 to 25 mcg/day; adjust dose by 12.5 to 25 mcg increments at 6- to 8-week intervals as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Adults with severe longstanding hypothyroidism:</i> Initial: 12.5 to 25 mcg/day; adjust dose by 12.5 to 25 mcg/day every 2 to 4 weeks as appropriate</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pregnant patients: </i>Dosage requirements may increase during pregnancy in patients with preexisting disease. If new onset hypothyroidism occurs initiate therapy with 1.6 mcg/kg/day (for severe hypothyroidism) <b>or</b> 1 mcg/kg/day (for mild hypothyroidism [TSH &lt;10 milliunits/L]) followed by appropriate dosage adjustments every 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, IV (off-label route [IM] and off-label use): ~75% of the oral dose by IV administration (ATA [Jonklaas 2014]); alternatively 50% of the previously established oral dose by IV or IM administration has been recommended (Levothyroxine injection Canadian product labeling 2017). <b>Note:</b> Bioavailability of the oral formulation is highly variable, but absorption has been measured to be ~80%, when the oral tablet formulation was administered in the recommended fasting state (Dickerson 2010; Fish 1987).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>TSH suppression:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Well-differentiated thyroid cancer (papillary and follicular):</i> Highly individualized; Doses &gt;2 mcg/kg/day may be needed to suppress TSH to &lt;0.1 milliunits/L in high-risk tumors. For intermediate-risk tumors, initial TSH suppression to 0.1 to 0.5 milliunits/L is recommended; for low-risk tumors, TSH may be maintained at or slightly below the lower limit of normal (0.1 to 0.5 milliunits/L [if low serum thyroglobulin levels]) or at 0.5 to 2 milliunits/L [if undetectable serum thyroglobulin levels or post-lobectomy] (ATA [Haugen 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Benign nodules and nontoxic multinodular goiter:</i> Routine use of T<sub>4</sub> for TSH suppression is not recommended in patients with benign thyroid nodules. In patients deemed appropriate candidates, treatment should never be fully suppressive (TSH &lt;0.1 milliunits/L) (AACE/ACE/AME [Gharib 2016]; ATA [Haugen 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myxedema coma or stupor:</b> IV: 300 to 500 mcg initially, followed by 50 to 100 mcg once daily until patient is able to tolerate oral administration; smaller doses should be considered in patients with cardiovascular disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations (off-label dose): Initial loading dose: 200 to 400 mcg; followed by a daily replacement dose of 1.2 mcg/kg/day (which is 75% of the 1.6 mcg/kg oral daily replacement dose reduced for IV administration); smaller doses should be considered for smaller or older patients and those with a history of coronary disease or arrhythmia; institute oral therapy after the patient improves clinically (ATA [Jonklaas 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cadaveric organ recovery (hormonal resuscitation) (off-label use):</b> IV: Initial: 20 mcg bolus followed by a continuous infusion of 10 mcg/hour administered to the brain-dead donor who is hemodynamically unstable requiring significant vasopressor support; give concomitantly with methylprednisolone, dextrose, and regular insulin (Salim 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Subclinical hypothyroidism (if treated) (off-label use):</b> Oral: Initial: 25 to 75 mcg/day, with higher doses usually required for those presenting with higher TSH values (ATA/AACE [Garber 2012]) <b>or</b> 1.5 mcg/kg/day (for patients without heart disease) <b>or</b> 25 or 50 mcg/day (for patients with cardiac disease) (ETA [Pearce 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188377\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=levothyroxine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Levothyroxine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypothyroidism (acquired or congenital):</b> Infants, Children, and Adolescents: Doses should be adjusted based on clinical response and laboratory parameters; on a weight basis, dosing is higher in infants and children than adults due to the higher metabolic clearance. Capsules are approved for use in children &ge;6 years of age and adolescents. <b>Note:</b> Hyperactivity in older children may be minimized by starting at 25% of the recommended dose and increasing each week by that amount until the full dose is achieved (4 weeks).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Oral:</i> Daily dosage based on body weight and age as listed below:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 3 months: 10 to 15 mcg/kg/dose once daily; in severe cases of hypothyroidism (serum T<sub>4</sub> &lt;5 mcg/dL), initiating at higher doses (12 to 17 mcg/kg/dose) may be necessary (AAP 2006; ATA [Jonklaas 2014]; Leger 2014; Selva 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;3 months of age to 6 months: 8 to 10 mcg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;6 months of age to 12 months: 6 to 8 mcg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 5 years: 5 to 6 mcg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">6 to 12 years: 4 to 5 mcg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;12 years of age but growth and puberty incomplete: 2 to 3 mcg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents with growth and puberty complete: 1.6 mcg/kg/day; refer to adult dosing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patient with cardiac disease: <b>Note:</b> Lower initial doses are recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: Initial: ~50% of target replacement dose; increase after 2 weeks based on free thyroxine levels (Leger 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents with growth and puberty complete: Initial: 12.5 to 25 mcg/day; adjust dose by 12.5 to 25 mcg increments at 6- to 8-week intervals as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>IV:</i> <b>Note:</b> The relative bioavailability of injectable and oral levothyroxine has not been established; use caution when switching patients from oral to IV as accurate dosing conversions have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: ~75% to 80% of the oral dose has been suggested (ATA [Jonklaas 2014]; Leger 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188366\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Doses should be adjusted based on clinical response and laboratory parameters.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypothyroidism:</b> Oral: Initial: 12.5 to 25 mcg/day; adjust dose every 6 to 8 weeks until euthyroid. Elderly patients may only require &lt;1 mcg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myxedema coma:</b> Refer to adult dosing; lower doses may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Subclinical hypothyroidism (if treated) (off-label use): </b>Oral: Initial dosing is generally lower than that required in the treatment of overt hypothyroidism; higher serum TSH targets may be appropriate in elderly patients (ATA/AACE [Garber 2012])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265597\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16265598\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24825220\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiac symptoms (onset or worsening): Manufacturer labeling recommends reducing dosage or withholding therapy for 7 days and then resuming therapy at reduced dosage. Specific dosing recommendations are not provided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188330\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tirosint: 13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mcg (1 ea); 200 mcg (1 ea); 500 mcg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levoxyl: 25 mcg [scored; contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levoxyl: 50 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levoxyl: 75 mcg [scored; contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levoxyl: 88 mcg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levoxyl: 100 mcg [scored; contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levoxyl: 112 mcg [scored; contains fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levoxyl: 125 mcg [scored; contains fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levoxyl: 137 mcg, 150 mcg [scored; contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levoxyl: 175 mcg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levoxyl: 200 mcg [scored; contains fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 25 mcg [scored; contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 50 mcg [scored; contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 75 mcg [scored; contains corn starch, fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 88 mcg [scored; contains corn starch, fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 100 mcg [scored; contains corn starch, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 112 mcg [scored; contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 125 mcg [scored; contains corn starch, fd&amp;c blue #1 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 137 mcg [scored; contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 150 mcg [scored; contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 175 mcg [scored; contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 200 mcg [scored; contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid: 300 mcg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 25 mcg [contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 50 mcg, 75 mcg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 75 mcg [contains fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 88 mcg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 88 mcg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 100 mcg [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 112 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 125 mcg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 137 mcg [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 150 mcg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 175 mcg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 175 mcg [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 200 mcg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 200 mcg [contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 300 mcg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid: 300 mcg [DSC] [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid Direct: 25 mcg [scored; contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid Direct: 50 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid Direct: 75 mcg, 88 mcg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid Direct: 100 mcg [scored; contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid Direct: 112 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid Direct: 125 mcg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid Direct: 150 mcg [scored; contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid Direct: 175 mcg [scored; contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid Direct: 200 mcg [scored; contains fd&amp;c red #40 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Unithroid Direct: 300 mcg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188314\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24825222\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:2em;\">Tablet, Oral, as sodium:</p>\n    <p style=\"text-indent:4em;\">Eltroxin: 50 mcg, 100 mcg, 150 mcg, 200 mcg, 300 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49345403\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Tirosint-Sol (levothyroxine oral solution): FDA approved December 2016; anticipated availability is currently unknown. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188334\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer consistently in the morning on an empty stomach, at least 30 to 60 minutes before food. Alternatively, may consistently administer at night 3 to 4 hours after the last meal (AACE/ATA [Garber 2012]; ATA [Jonklaas 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: Must be swallowed whole; do not cut, crush, or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: May be crushed and suspended in 5 to 10 mL of water; suspension should be used immediately. Levoxyl should be administered with a full glass of water to prevent gagging (due to tablet swelling).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasogastric tube: Bioavailability of levothyroxine is reduced if administered with enteral tube feeds. Since holding feedings for at least 1 hour before and after levothyroxine administration may not completely resolve the interaction, an increase in dose (eg, additional 25 mcg) may be necessary (Dickerson 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: May be administered by IV injection; may also be administered IM when oral administration is not feasible (off-label route).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cadaveric organ recovery (hormonal resuscitation) (off-label use):</i> After IV bolus administration, may administer as a continuous infusion (Salim 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188333\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypothyroidism: Replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology. Specific indications include primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism. <b>Note:</b> Levothyroxine monotherapy is recommended as the preferred thyroid preparation for the treatment of hypothyroidism (ATA [Jonklaas 2014]; ES [Fleseriu 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pituitary thyrotropin-stimulating hormone suppression: An adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injectable:</b> Treatment of myxedema coma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726760\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cadaveric organ recovery (hormonal resuscitation); Subclinical hypothyroidism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188391\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levothyroxine may be confused with lamoTRIgine, Lanoxin, levoFLOXacin, liothyronine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levoxyl may be confused with Lanoxin, Levaquin, Luvox </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synthroid may be confused with Symmetrel</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">To avoid errors due to misinterpretation of a decimal point, always express dosage in mcg (<b>not</b> mg).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188321\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, cardiac arrest, cardiac arrhythmia, cardiac failure, flushing, hypertension, increased pulse, myocardial infarction, palpitations, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, choking sensation (Levoxyl), emotional lability, fatigue, headache, heat intolerance, hyperactivity, insomnia, irritability, myasthenia, nervousness, pseudotumor cerebri (children), seizure (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Menstrual disease, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, diarrhea, dysphagia (Levoxyl), gag reflex (Levoxyl), increased appetite, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Infertility</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity (to inactive ingredients; symptoms include urticaria, pruritus, rash, flushing, angioedema, GI symptoms, fever, arthralgia, serum sickness, wheezing)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Decreased bone mineral density, slipped capital femoral epiphysis (children), tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Dysgeusia (Syed 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188337\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: There are no contraindications listed in the manufacturer's labeling when used for labeled indication (treatment of myxedema coma); consider contraindications for oral therapy if using as a temporary substitute for oral treatment (off-label use) in patients with chronic hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Uncorrected adrenal insufficiency; <b>Note:</b> Product labels may vary; also consult product labels. Reported hypersensitivity to levothyroxine or any component of the formulation is not considered an absolute contraindication (Jonklass 2014); refer to Warnings/Precautions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188318\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated. Treatment with glucocorticoids should precede levothyroxine therapy in patients with adrenal insufficiency. Use is contraindicated in patients with uncorrected adrenal insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benign thyroid nodules: Appropriate use: Routine use of T<sub>4</sub> for thyroid stimulating hormone (TSH) suppression is not recommended in patients with benign thyroid nodules. Treatment should never be fully suppressive (TSH &lt;0.1 milliunits/L) (AACE/ACE/AME [Gharib 2016]; ATA [Haugen 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Use of T<sub>4</sub> may be considered in association with iodine supplementation only in young patients residing in iodine-deficient areas with small thyroid nodules and no evidence of functional autonomy (AACE/ACE/AME [Gharib 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Use should be avoided in postmenopausal women, elderly patients, patients with cardiovascular disease, osteoporosis, large thyroid nodules or long-standing goiters, or low-normal TSH levels (AACE/ACE/AME [Gharib 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution and reduce dosage in patients with cardiovascular disease; patients with developing or worsening cardiac symptoms should have their dose reduced or therapy withheld for 7 days and then resumed at a reduced dose. Chronic hypothyroidism predisposes patients to coronary artery disease; monitor patients closely for development of cardiac ischemia. Similarly, patients with heart failure and hypothyroidism should be closely followed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus (may worsen glycemic control) and diabetes insipidus (thyroid hormone increases glomerular filtration rate and downregulates aquaporin channels in the renal tubules, which could affect urinary output) (Mariani 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteoporosis: Long-term therapy can decrease bone mineral density. Postmenopausal women and women using suppressive doses should receive the lowest dose necessary for clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; suppressed TSH levels may increase risk of atrial fibrillation and mortality secondary to cardiovascular disease (Gharib 2016; Parle 2001). Increase dose slowly and monitor for signs/symptoms of angina.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Levoxyl: Product may rapidly swell and disintegrate, causing choking or gagging (should be administered with a full glass of water); use caution in patients with dysphagia or other swallowing disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Switching between different levothyroxine products may result in variations in the administered dose and altered TSH values and is not generally recommended; if formulations are changed, close monitoring of TSH is recommended (ATA [Jonklaas 2014]). Pediatric patients with congenital hypothyroidism may be more sensitive to changes in formulation (Carswell 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Patients with reported hypersensitivity to levothyroxine may be managed with dose reductions and slow titration, by switching formulations or products, or referral to an allergist (Jonklaas 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight reduction (off-label use): <b>[US Boxed Warning]: Thyroid supplements are ineffective and potentially toxic when used for the treatment of obesity or for weight reduction, especially in euthyroid patients. High doses may produce serious or even life-threatening toxic effects, particularly when used with some anorectic drugs (eg, sympathomimetic amines).</b> Levothyroxine, either alone or with other concomitant therapeutic agents, should not be used for the treatment of obesity or for weight loss.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299600\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188323\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9557&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: Thyroid Products may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apalutamide: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Levothyroxine. Management: Separate oral administration of iron-containing multivitamins and levothyroxine by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and orlistat  by a least 4 hours. Monitor patients closely for signs and symptoms of hypothyroidism.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patiromer: May decrease the serum concentration of Levothyroxine. Management: Administer oral levothyroxine at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piracetam: May enhance the adverse/toxic effect of Thyroid Products. Specifically, symptoms including confusion, irritability, and sleep disorder have been described during concomitant use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polaprezinc: May decrease the serum concentration of Levothyroxine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raloxifene: May decrease the absorption of Levothyroxine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the serum concentration of Levothyroxine. Management: Consider separating administration of sevelamer and levothyroxine by at least several hours whenever possible in order to decrease the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Somatropin: May diminish the therapeutic effect of Thyroid Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Levothyroxine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucroferric Oxyhydroxide: May decrease the serum concentration of Levothyroxine. Management: Avoid the use of oral/enteral levothyroxine and sucroferric oxyhydroxide in combination.  No interaction is anticipated with parenteral levothyroxine administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Thyroid Products may enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188355\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Taking levothyroxine with enteral nutrition may cause reduced bioavailability and may lower serum thyroxine levels leading to signs or symptoms of hypothyroidism. Soybean flour (infant formula),  soy, grapefruit juice, espresso coffee, cottonseed meal, walnuts, and dietary fiber may interfere with absorption of levothyroxine from the GI tract. Management: Take in the morning on an empty stomach at least 30 minutes before food. Consider an increase in dose if taken with enteral tube feed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188326\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">A (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188341\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Endogenous thyroid hormones minimally cross the placenta; the fetal thyroid becomes active around the end of the first trimester. Levothyroxine has not been shown to increase the risk of congenital abnormalities.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled maternal hypothyroidism may result in adverse neonatal outcomes (eg, premature birth, low birth weight, and respiratory distress) and adverse maternal outcomes (eg, spontaneous abortion, pre-eclampsia, stillbirth, and premature delivery). To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Thyroid function should be monitored every 4 weeks during the first half of pregnancy, at least once between weeks 26 and 32, and ~6 weeks postpartum. Levothyroxine is considered the treatment of choice for the control of hypothyroidism during pregnancy. Due to alterations of endogenous maternal thyroid hormones, the levothyroxine dose may need to be increased during pregnancy and the dose usually needs to be decreased after delivery (Stagnaro-Green 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188342\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endogenous thyroid hormones are minimally found in breast milk. The manufacturer recommends that caution be used if administered to a nursing woman.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The amount of endogenous thyroxine found in breast milk does not influence infant plasma thyroid values (van Wassenaer 2002). Levothyroxine was not found to cause adverse events to the infant or mother during breastfeeding (Ito 1993). Adequate thyroid hormone concentrations are required to maintain normal lactation. Appropriate levothyroxine doses should be continued during breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188328\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants: Monitor closely for cardiac overload, arrhythmias, and aspiration from avid suckling</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants/children: Monitor closely for under/overtreatment. Undertreatment may decrease intellectual development and linear growth, and lead to poor school performance due to impaired concentration and slowed mentation. Overtreatment may adversely affect brain maturation, accelerate bone age (leading to premature closure of the epiphyses and reduced adult height); craniosynostosis has been reported in infants. Treated children may experience a period of catch-up growth. Monitor TSH and total or free T<sub>4</sub> at 2 and 4 weeks after starting treatment; every 1 to 2 months for first year of life; every 2 to 3 months during years 1 to 3; every 3 to 12 months until growth completed. Perform routine clinical examinations at regular intervals (to assess mental and physical growth and development).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: TSH 4 to 6 weeks after treatment initiation or dose changes, 4 to 6 months after adequate replacement dose determined, followed by every 12 months thereafter (or more frequently depending on clinical situation) (ATA [Jonklaas 2014]); T<sub>4</sub>; heart rate, blood pressure, clinical signs of hypo- and hyperthyroidism; TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage in primary thyroid dysfunction. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T<sub>4</sub> remains low and TSH is within normal limits, an evaluation of &ldquo;free&rdquo; (unbound) T<sub>4</sub> is needed to evaluate further increase in dosage. Free T<sub>4</sub> (not TSH) should be monitored to guide treatment in patients with central hypothyroidism (ATA/AACE [Garber 2012]; ES [Fleseriu 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bone mineral density (particularly with long term use in postmenopausal women)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188331\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">T<sub>4</sub> (thyroxine) serum concentrations: Adults: ~4 to 12 mcg/dL (SI: 51 to 154 nmol/L). <b>Note:</b> Normal range in pregnancy: ~5.5 to 16 mcg/dL (SI: ~71 to 206 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">T<sub>4</sub> free (free thyroxine; free T<sub>4</sub>) serum concentrations: Adults: 0.7 to 1.8 ng/dL (SI: 9 to 23 pmol/L). A target range in the mid to upper half of the reference range has been suggested in patients with central hypothyroidism (ES [Fleseriu 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">T<sub>3</sub> total (triiodothyronine; total T<sub>3</sub>) serum concentrations: Adults: 80 to 230 ng/dL (SI: 1.2 to 3.5 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid-stimulating hormone (TSH) serum concentrations: Adults: Varies by laboratory and assay used; refer to laboratory provided reference range. If an upper and lower limit of normal for a third generation TSH assay is not available, a reference range of 0.45 to 4.12 milliunits/L should be considered (ATA/AACE [Garber 2012]). A higher target range of 4 to 6 milliunits/L has been suggested in patients &gt;70 years of age (ATA [Jonklaas 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Subclinical hypothyroidism (elevated TSH; free T<sub>4</sub> within normal range):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe (TSH &ge;10 milliunits/L): These patients are at increased risk for heart failure and cardiovascular mortality and should be considered for treatment with L-thyroxine (ATA/AACE [Garber 2012]; ETA [Pearce 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate (TSH 4 to 10 milliunits/L): Decision for when to treat should be tailored to individual patient based on age, symptoms, and cardiovascular risk (ATA/AACE [Garber 2012]; ETA [Pearce 2013])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188317\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Levothyroxine (T<sub>4</sub>) is a synthetic form of thyroxine, an endogenous hormone secreted by the thyroid gland. T<sub>4</sub> is converted to its active metabolite, L-triiodothyronine (T<sub>3</sub>). Thyroid hormones (T<sub>4</sub> and T<sub>3</sub>) then bind to thyroid receptor proteins in the cell nucleus and exert metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores, and stimulates protein synthesis, increases basal metabolic rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188336\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: 3 to 5 days; IV: Within 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Erratic (40% to 80% [per manufacturer]); may be decreased by age and specific foods and drugs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;99% bound to plasma proteins including thyroxine-binding globulin, thyroxine-binding prealbumin, and albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to triiodothyronine (T<sub>3</sub>; active); ~80% thyroxine (T<sub>4</sub>) deiodinated in kidney and periphery; glucuronidation/conjugation also occurs; undergoes enterohepatic recirculation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral tablets: 64% (nonfasting state) to 79% to 81% (fasting state) (Dickerson 2010; Fish 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 2 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Euthyroid: 6 to 8 days; Hypothyroid: 9 to 10 days; Hyperthyroid: 3 to 4 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (major route of elimination; decreases with age); feces (~20%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188340\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tirosint Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">13 mcg (28): $143.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (28): $143.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (28): $143.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg (28): $143.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">88 mcg (28): $143.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (28): $143.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">112 mcg (28): $143.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (28): $143.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">137 mcg (28): $143.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mcg (28): $143.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Levothyroxine Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (1): $126.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (1): $253.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg (1): $633.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Levo-T Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (90): $39.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (90): $44.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg (90): $49.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">88 mcg (90): $50.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (90): $50.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">112 mcg (90): $58.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (90): $59.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">137 mcg (90): $60.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mcg (90): $61.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">175 mcg (90): $72.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (90): $72.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg (90): $93.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Levothyroxine Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (1000): $436.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (1000): $496.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg (1000): $548.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">88 mcg (100): $55.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (1000): $561.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">112 mcg (100): $64.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (1000): $658.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">137 mcg (90): $60.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mcg (1000): $677.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">175 mcg (100): $80.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (90): $72.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg (90): $97.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Levoxyl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (100): $79.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (100): $90.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg (100): $99.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">88 mcg (100): $101.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (100): $102.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">112 mcg (100): $118.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (100): $119.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">137 mcg (100): $121.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mcg (100): $123.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">175 mcg (100): $146.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (100): $147.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Synthroid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (90): $127.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (100): $144.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg (100): $143.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">88 mcg (90): $127.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (100): $145.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">112 mcg (90): $127.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (100): $144.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">137 mcg (90): $127.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mcg (100): $143.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">175 mcg (90): $127.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (100): $145.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg (90): $130.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Unithroid Direct Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (84): $35.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (84): $35.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg (84): $35.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">88 mcg (84): $35.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (84): $35.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">112 mcg (84): $35.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (84): $35.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mcg (84): $35.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">175 mcg (84): $35.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (84): $35.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg (84): $35.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Unithroid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg (100): $328.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg (100): $328.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg (100): $328.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">88 mcg (100): $329.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg (100): $330.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">112 mcg (100): $330.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (100): $331.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">137 mcg (100): $331.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mcg (100): $331.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">175 mcg (100): $332.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg (100): $332.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg (100): $333.02</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188344\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bagotiroks (UA);</li>\n      <li>Berlthyrox (DE);</li>\n      <li>Cynocuatro (MX);</li>\n      <li>Droxine (AU, NZ);</li>\n      <li>Eferox (QA);</li>\n      <li>Elthyro (TH);</li>\n      <li>Elthyrone (BE);</li>\n      <li>Eltroxin (AE, BD, BF, BH, BJ, BM, BZ, CH, CI, CY, CZ, DK, EG, ET, GB, GH, GM, GN, GY, HK, IE, IL, IQ, IR, JO, JP, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, OM, PH, PK, QA, SA, SC, SD, SL, SN, SR, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Eurolev (PH);</li>\n      <li>Euthyrox (AE, AR, AT, BE, BG, BH, BR, CH, CN, CY, CZ, DE, EE, HR, HU, ID, IS, JO, KW, LB, LU, LV, MY, PH, PL, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TZ, VE);</li>\n      <li>Eutirox (BB, BS, CL, CR, CU, DO, ES, GT, HN, IT, JM, MX, NI, NL, PA, PE, SV, TT);</li>\n      <li>Eutroxsig (AU, NZ);</li>\n      <li>Eutyroks (UA);</li>\n      <li>Levaxin (SE);</li>\n      <li>Levhexal (MX);</li>\n      <li>Levothyrox (FR);</li>\n      <li>Levotirox (IT);</li>\n      <li>Levotiroxina (EC);</li>\n      <li>Narval (UY);</li>\n      <li>Oroxine (AU, IE, MY);</li>\n      <li>Pondtroxin (TH);</li>\n      <li>Synox (IN);</li>\n      <li>Synroid (BD);</li>\n      <li>Synthroid (BR, CO, KR, KW, NZ, QA);</li>\n      <li>Synthyroxine (KR);</li>\n      <li>T4 (PY);</li>\n      <li>T4KP (TH);</li>\n      <li>Thevier (DE);</li>\n      <li>Thormon (BD);</li>\n      <li>Throid (BD);</li>\n      <li>Thydin (PH);</li>\n      <li>Thynor (BD);</li>\n      <li>Thyradin S (JP);</li>\n      <li>Thyrax (BE, CZ, ID, PT);</li>\n      <li>Thyrax Duotab (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Thyrex (AT);</li>\n      <li>Thyro-4 (GR);</li>\n      <li>Thyroid-S (TW);</li>\n      <li>Thyromega (LK);</li>\n      <li>Thyronorm (LK);</li>\n      <li>Thyrosit (TH);</li>\n      <li>Thyrostad (VN);</li>\n      <li>Thyrox (LK);</li>\n      <li>Thyroxin (FI);</li>\n      <li>Thyvex (LK);</li>\n      <li>Tiroidine (MX);</li>\n      <li>Tiroxin (CO, EC);</li>\n      <li>Tyraq (HR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Rose SR, Section on Endocrinology and Committee on Genetics, American Thyroid Association, et al. Update of Newborn Screening and Therapy for Congenital Hypothyroidism. <i>Pediatrics</i>. 2006;117(6):2290-2303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/16740880/pubmed\" target=\"_blank\" id=\"16740880\">16740880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer LA, &ldquo;Simulations of Levothyroxine Bioavailability Using a Single Dose Protocol,&rdquo; <i>Am J Ther</i>, 1995, 2:414-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/11850686/pubmed\" target=\"_blank\" id=\"11850686\">11850686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berkner PD, Starkman H, and Person N, &ldquo;Acute L-Thyroxine Overdose: Therapy With Sodium Ipodate: Evaluation of Clinical and Physiologic Parameters,&rdquo; <i>J Emerg Med</i>, 1991, 9(3):129-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/2050969/pubmed\" target=\"_blank\" id=\"2050969\">2050969</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Binimelis J, Bassas L, Marruecos L, et al. Massive thyroxine intoxication: evaluation of plasma extraction. <i>Intensive Care Med.</i> 1987;13(1):33-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/3558934/pubmed\" target=\"_blank\" id=\"3558934\">3558934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23264396\"></a>Carswell JM, Gordon JH, Popovsky E, Hale A, Brown RS. Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism.<i> J Clin Endocrinol Metab</i>. 2013;98(2):610-617. doi: 10.1210/jc.2012-3125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/23264396/pubmed\" target=\"_blank\" id=\"23264396\">23264396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cytomel (liothyronine) [prescribing information]. New York, NY: Pfizer Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Groot JW, Zonnenberg BA, Plukker JT, et al, &ldquo;Imatinib Induces Hypothyroidism in Patients Receiving Levothyroxine,&rdquo; <i>Clin Pharmacol Ther</i>, 2005, 78(4):433-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/16198662/pubmed\" target=\"_blank\" id=\"16198662\">16198662</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dickerson DN, Maish GO 3rd, Minard G, et al, &ldquo;Clinical Relevancy of Levothyroxine &ndash; Continuous Enteral Nutrition Interaction,&rdquo; <i>Nutr Clin Pract</i>, 2010, 25(6):646-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/21139130/pubmed\" target=\"_blank\" id=\"21139130\">21139130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eltroxin (levothyroxine) [product monograph]. Concord, Ontario, Canada: Triton Pharma Inc.; May 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Escalante DA, Arem N, and Arem R, &ldquo;Assessment of Interchangeability of Two Brands of Levothyroxine Preparations With a Third-Generation TSH Assay,&rdquo; <i>Am J Med</i>, 1995, 98(4):374-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/7709950/pubmed\" target=\"_blank\" id=\"7709950\">7709950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. <i>N Engl J Med</i>. 1987;316(13):764-770.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/3821822/pubmed\" target=\"_blank\" id=\"3821822\">3821822</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(11):3888&ndash;3921. doi: 10.1210/jc.2016-2118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/27736313/pubmed\" target=\"_blank\" id=\"27736313\">27736313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23246686\"></a>Garber KR, Cobin RH, Gharib H, et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. <i>Endocr Pract</i>. 2012;18(6):988-1028.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/23246686/pubmed\" target=\"_blank\" id=\"23246686\">23246686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gharib H, Papini E, Garber JR, et al; AACE/ACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules--2016 update. Endocr Pract. 2016;22(5):622-639. doi: 10.4158/EP161208.GL.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/27167915/pubmed\" target=\"_blank\" id=\"27167915\">27167915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gorman RL, Chamberlain JM, Rose SR, et al, &ldquo;Massive Levothyroxine Overdose: High Anxiety - Low Toxicity,&rdquo; <i>Pediatrics</i>, 1988, 82(4):666-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/3174321/pubmed\" target=\"_blank\" id=\"3174321\">3174321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gupta VD, &ldquo;Stability of Levothyroxine Sodium Injection in Polypropylene Syringes,&rdquo; <i>Int J Pharm Compound</i>, 2000, 4(6):482-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Helfand M and Crapo LM, &ldquo;Monitoring Therapy in Patients Taking Levothyroxine,&rdquo; <i>Ann Intern Med</i>, 1990, 113(6):450-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/2143640/pubmed\" target=\"_blank\" id=\"2143640\">2143640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i>. 2016;26(1):1-133. doi: 10.1089/thy.2015.0020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/26462967/pubmed\" target=\"_blank\" id=\"26462967\">26462967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. <i>Thyroid</i>. 2014;24(12):1670-1751.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/25266247/pubmed\" target=\"_blank\" id=\"25266247\">25266247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson DG and Campbell S, &ldquo;Hormonal and Metabolic Agents,&rdquo; <i>Geriatric Pharmacology</i>, Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 427-50.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24747464\"></a>Joseph B, Aziz H, Pandit V, et al. Levothyroxine therapy before brain death declaration increases the number of solid organ donations. <i>J Trauma Acute Care Surg</i>. 2014;76(5):1301-1305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/24747464/pubmed\" target=\"_blank\" id=\"24747464\">24747464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulig K, Golightly LK, and Rumack BH, &ldquo;Levothyroxine Overdose Associated With Seizures in a Young Child,&rdquo; <i>JAMA</i>, 1985, 254(15):2109-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/4046139/pubmed\" target=\"_blank\" id=\"4046139\">4046139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    L&eacute;ger J, Olivieri A, Donaldson M, et al; ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE; Congenital Hypothyroidism Consensus Conference Group. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. <i>Horm Res Paediatr</i>. 2014;81(2):80-103. doi: 10.1159/000358198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/24662106/pubmed\" target=\"_blank\" id=\"24662106\">24662106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levothyroxine sodium for injection [prescribing information]. Lake Zurich, Il: Fresenius Kabi USA LLC; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levothyroxine sodium for injection [Canadian product monograph]. Blainville, Quebec, Canada: Laboratorie Riva Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liwanpo L and Hershman JM, &ldquo;Conditions and Drugs Interfering With Thyroxine Absorption,&rdquo; <i>Best Pract Res Clin Endocrinol Metab</i>, 2009, 23(6):781-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/19942153/pubmed\" target=\"_blank\" id=\"19942153\">19942153</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandel SH, Magnusson AR, Burton BT, et al, &ldquo;Massive Levothyroxine Ingestion: Conservative Management,&rdquo; <i>Clin Pediatr (Phila)</i>, 1989, 28(8):374-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/2758719/pubmed\" target=\"_blank\" id=\"2758719\">2758719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mariani LH, Berns JS. The renal manifestations of thyroid disease. <i>J Am Soc Nephrol</i>. 2012;23(1):22-26. doi: 10.1681/ASN.2010070766.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/22021708/pubmed\" target=\"_blank\" id=\"22021708\">22021708</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mayor GH, Orlando T, and Kurtz N, &ldquo;Limitations of Levothyroxine Bioequivalence Evaluation: Analysis of an Attempted Study,&rdquo; <i>Am J Ther</i>, 1995, 2:417-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/11850687/pubmed\" target=\"_blank\" id=\"11850687\">11850687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parle JV, Maisonneuve P, Sheppard MC, et al, &ldquo;Prediction of All-Cause and Cardiovascular Mortality in Elderly People from One Low Serum Thyrotropin Result: A 10-year Cohort Study,&rdquo; <i>Lancet</i>, 2001, 358(9285):861-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/11567699/pubmed\" target=\"_blank\" id=\"11567699\">11567699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24783053\"></a>Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. <i>Eur Thyroid J</i>. 2013;2(4):215-228.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/24783053/pubmed\" target=\"_blank\" id=\"24783053\">24783053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12605114\"></a>Rosendale JD, Kauffman HM, McBride MA, et al, &ldquo;Aggressive Pharmacologic Donor Management Results in More Transplanted Organs,&rdquo; <i>Transplantation</i>, 2003a, 75(4):482-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/12605114/pubmed\" target=\"_blank\" id=\"12605114\">12605114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12717226\"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. <i>Transplantation</i>. 2003b;75(8):1336-1341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/12717226/pubmed\" target=\"_blank\" id=\"12717226\">12717226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12243491\"></a>Rosengard BR, Feng S, Alfrey EJ, et al, &ldquo;Report of the Crystal City Meeting to Maximize the Use of Organs Recovered From the Cadaver Donor,&rdquo; <i>Am J Transplant</i>, 2002, 2(8):701-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/12243491/pubmed\" target=\"_blank\" id=\"12243491\">12243491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17488392\"></a>Salim A, Martin M, Brown C, et al. Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation.<i>Clin Transplant</i>, 2007;21(3):405-409.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/17488392 /pubmed\" target=\"_blank\" id=\"17488392 \">17488392 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanders LR, &ldquo;Pituitary, Thyroid, Adrenal and Parathyroid Diseases in the Elderly,&rdquo; <i>Geriatric Medicine</i>, 1990, 475-87.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sawin CT, Geller A, Hershman JM, et al, &ldquo;The Aging Thyroid. The Use of Thyroid Hormone in Older Persons,&rdquo; <i>JAMA</i>, 1989, 261(18):2653-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/2709545/pubmed\" target=\"_blank\" id=\"2709545\">2709545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Selva KA, Mandel SH, Rien L, et al. Initial Treatment Dose of L-thyroxine in Congenital Hypothyroidism. <i>J Pediatr.</i> 2002;141(6):786-792.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/12461494/pubmed\" target=\"_blank\" id=\"12461494\">12461494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh N, Singh P, and Hershman J. &ldquo;Effect of Calcium Carbonate on the Absorption of Levothyroxine,&rdquo; <i>JAMA</i>, 2000, 283:2822-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/10838651/pubmed\" target=\"_blank\" id=\"10838651\">10838651</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stagnaro-Green A, Abalovich M, Alexander E, et al; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum, Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. <i>Thyroid</i>. 2011;21(10):1081-1125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/21787128/pubmed\" target=\"_blank\" id=\"21787128\">21787128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strong DK, Decarie D, and Ensom MHH, &ldquo;Stability of Levothyroxine in Sodium Chloride for IV Administration,&rdquo; <i>Can J Hosp Pharm</i>, 2010, 63(6):437-43.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26899755\"></a>Syed Q, Hendler KT, Koncilja K. The impact of aging and medical status on dysgeusia. <i>Am J Med</i>. 2016;129(7):753.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/26899755/pubmed\" target=\"_blank\" id=\"26899755\">26899755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synthroid (levothyroxine) [prescribing information]. North Chicago, Il: AbbVie Inc; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synthroid (levothyroxine) [product monograph]. St-Laurent, Quebec, Canada: BGP Pharma ULC; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tirosint (levothyroxine) [prescribing information]. Cranford, NJ: Akrimax Pharmaceuticals; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunget CL, Clark RF, Turchen SG, et al, &ldquo;Raising the Decontamination Level for Thyroid Hormone Ingestions,&rdquo; <i>Am J Emerg Med</i>, 1995, 13(1):9-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/7832964/pubmed\" target=\"_blank\" id=\"7832964\">7832964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Unithroid (levothyroxine sodium) [prescribing information]. Bridgewater, NJ: Gemini Laboratories; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Wassenaer AG, Stulp MR, Valianpour F, et al, The quantity of thyroid hormone in human milk Is too low to influence plasma thyroid hormone levels in the very preterm infant. <i>Clin Endocrinol (Oxf)</i>. 2002;56(5):621-627.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/12030913/pubmed\" target=\"_blank\" id=\"12030913\">12030913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watts NB, &ldquo;Use of a Sensitive Thyrotropin Assay for Monitoring Treatment With Levothyroxine,&rdquo; <i>Arch Intern Med</i>, 1989, 149(2):309-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/2644903/pubmed\" target=\"_blank\" id=\"2644903\">2644903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12176957\"></a>Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus Conference Report: Maximizing Use of Organs Recovered from the Cadaver Donor: Cardiac Recommendations: March 28-29, 2001, Crystal City, Va. <i>Circulation</i>. 2002;106(7):836-841.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levothyroxine-drug-information/abstract-text/12176957/pubmed\" target=\"_blank\" id=\"12176957\">12176957</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9557 Version 231.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709010\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F188360\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F188361\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F188382\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F188365\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F188377\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F188366\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16265597\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16265598\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F24825220\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F188330\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F188314\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F24825222\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49345403\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F188334\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F188333\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726760\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F188391\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F188321\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F188337\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F188318\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299600\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F188323\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F188355\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F188326\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F188341\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F188342\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F188328\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F188331\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F188317\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F188336\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F188340\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F188344\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9557|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=levothyroxine-patient-drug-information\" class=\"drug drug_patient\">Levothyroxine: Patient drug information</a></li><li><a href=\"topic.htm?path=levothyroxine-pediatric-drug-information\" class=\"drug drug_pediatric\">Levothyroxine: Pediatric drug information</a></li></ul></div></div>","javascript":null}